Johnson & Johnson

Johnson & Johnson announced the retirement of Executive Vice President Jennifer Taubert, with Tom Cavanaugh appointed to succeed her, effective September 1, 2026.

Johnson & Johnson completes acquisition of Firefly Bio for $1 billion and enters strategic collaboration with Sail Biomedicines, impacting 2026 and 2027 EPS guidance.

Johnson & Johnson announced robust second-quarter 2026 results, with sales reaching $25.3 billion and earnings per share at $2.27, leading the company to increase its full-year financial guidance.

Johnson & Johnson announced strong first-quarter 2026 results, with sales up 9.9% and earnings per share of $2.14, leading the company to raise its full-year 2026 guidance.

Johnson & Johnson announced robust fourth-quarter and full-year 2025 financial results, driven by strong operational growth and significant innovation across its Innovative Medicine and MedTech segments.

Johnson & Johnson reported strong third-quarter 2025 results, raising its full-year sales outlook, and announced its intent to separate its Orthopaedics business, DePuy Synthes.

Johnson & Johnson announced robust Q2 2026 financial results, with sales up 6.6% year-over-year, driven by strong performance in both Innovative Medicine and MedTech segments.

Johnson & Johnson reported a 9.9% increase in first-quarter sales to $24.1 billion, with the Innovative Medicine segment showing robust growth, partially offset by declines in Immunology.

Johnson & Johnson reported a 104% surge in net earnings for the fiscal nine months ended September 28, 2025, primarily driven by a $7 billion reversal of talc litigation reserves, alongside 5.0% total sales growth.

Johnson & Johnson's second quarter and first half 2025 financial results show significant net earnings growth, primarily due to the reversal of a substantial talc litigation reserve, alongside robust performance in Innovative Medicine and MedTech segments boosted by recent acquisitions.

Johnson & Johnson's Q1 2025 results reflect a significant reversal of talc reserves and the impact of strategic acquisitions, alongside operational growth in key segments.

Johnson & Johnson's Q3 2024 results show a mixed performance with revenue growth offset by significant charges related to talc litigation and strategic acquisitions.

Johnson & Johnson reported robust financial performance in fiscal year 2025 with 6.0% sales growth and a significant increase in earnings before taxes, while advancing its strategic plan to separate its Orthopaedics business.

Johnson & Johnson's 2024 annual report reveals a 4.3% increase in worldwide sales, driven by growth in both Innovative Medicine and MedTech segments, alongside strategic acquisitions and R&D investments.

Johnson & Johnson's 2023 10-K filing reveals a 6.5% increase in worldwide sales, significant investments in R&D, and a strategic shift following the separation of its Consumer Health business.

Vanessa Broadhurst, EVP, Global Corp Affairs of Johnson & Johnson, sold 23,054 shares of common stock on July 20, 2026 for $251.27 per share.

Johnson & Johnson EVP Kathryn Wengel exercised 10,000 stock options and subsequently sold the shares on June 11, 2026.

Johnson & Johnson Director Eugene A. Woods acquired 161.089 deferred share units as part of the company's director compensation plan.

Johnson & Johnson director Daniel E. Pinto acquired 134.241 deferred share units as part of the company's director fee plan.

Johnson & Johnson Director Marillyn A. Hewson acquired 214.786 deferred share units as part of the company's director compensation plan.

Johnson & Johnson executive John C. Reed reported transactions involving restricted stock units and common stock, including awards under the company's Long-Term Incentive Plan.

Johnson & Johnson has filed a definitive proxy statement with the Securities and Exchange Commission.

Johnson & Johnson's upcoming annual meeting will address director elections, executive compensation, and shareholder proposals on severance packages and human rights impact assessments.

Johnson & Johnson has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) pertaining to Section 14(a) of the Securities Exchange Act of 1934.

A shareholder proposal regarding the impact of extended patent exclusivities on patient access has been withdrawn from Johnson & Johnson's upcoming Annual Meeting.

Johnson & Johnson's 2024 proxy statement outlines key governance matters, including director elections, executive compensation, and shareholder proposals.

Johnson & Johnson's Q1 2026 13F filing reveals a diverse portfolio of investments, with a significant focus on biotechnology and healthcare innovation.

Johnson & Johnson filed an amended 13F-HR report, restating its equity holdings for the quarter ended December 31, 2025, totaling $555 million.

Johnson & Johnson filed an amended 13F report, restating its institutional investment holdings totaling over $503 million for the quarter ended September 30, 2025.

Johnson & Johnson's latest 13F filing reveals its investment portfolio for the quarter ended December 31, 2025, totaling over $554 million across 17 companies.

Johnson & Johnson filed its Form 13F-HR, revealing its equity holdings totaling over $503 million as of September 30, 2025.

Johnson & Johnson filed its Q2 2025 Form 13F-HR, revealing a total equity portfolio value of $334.1 million across 20 distinct holdings.

Vanguard Capital Management has filed a Schedule 13G reporting a 7.49% beneficial ownership stake in Johnson & Johnson common stock.

Johnson & Johnson and its subsidiary JJDC have amended their Schedule 13G filing, reporting a combined beneficial ownership of 2.9% in Rallybio Corporation as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Johnson & Johnson following an internal realignment that disaggregated reporting responsibilities.

The Vanguard Group filed an amended Schedule 13G for Johnson & Johnson, reporting a 10.1% beneficial ownership and detailing an internal realignment affecting its reporting structure.

Johnson & Johnson and its subsidiary JJDC, Inc. have filed an amendment to their Schedule 13G, confirming a 15.4% beneficial ownership in CVRx, Inc.

Johnson & Johnson and its subsidiary JJDC have reduced their beneficial ownership in Rapport Therapeutics, Inc. to 4.9% of common stock.